Diagnosis and Allergen Identification of Perioperative Anaphylaxis
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jan 20, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding and identifying the causes of perioperative anaphylaxis, which is a severe allergic reaction that can happen during or after surgery. The researchers aim to improve how doctors can diagnose and manage these reactions by looking at a substance called serum tryptase, which can help confirm if an anaphylactic reaction has occurred. Additionally, the study will explore how skin testing can help identify specific allergens so that patients can avoid these triggers in future surgeries.
To participate in this trial, individuals must be at least 18 years old and either have experienced an allergic reaction during surgery or have a history of suspected reactions in the operating room. Participants will undergo tests to help identify any allergens they may be sensitive to. It's important to note that this trial is not yet recruiting participants, and anyone who is interested will need to meet specific eligibility criteria to join. Overall, this study aims to enhance safety and care for patients undergoing surgery by better understanding allergic reactions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 2 years or over;
- • Suspected anaphylaxis in the operating rooms, or history of suspected anaphylaxis in the operating room.
- Exclusion Criteria:
- • Refuse to participate;
- • Other conditions that are considered unsuitable for study participation.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported